Role of Bone Marrow Transplantation in the Disease Pathway of Myeloma

In multiple myeloma, autologous stem cell transplantation (ASCT) has been considered a standard of care in younger patients. The introduction of novel agents (i.e., thalidomide, lenalidomide, and bortezomib) may change this scenario. These agents can be administered before or after ASCT with the goal of increasing the complete remission (CR) rate and prolonging remission. For instance, thalidomide given as maintenance therapy after double ASCT increases CR rate, event-free survival (EFS), and overall survival. Moreover, combinations of conventional chemotherapy with novel agents such as thalidomide or bortezomib yield CR rates and EFS comparable to those achieved with standard single ASCT. Prospective randomized studies are needed to evaluate the impact of novel agents versus or in combination with ASCT. Myeloablative conditioning regimens before allogeneic stem cell transplantation are being replaced with concurrent autologous-transplantation and reduced-intensity conditioning allogeneic stem cell transplantation. Transplant-related mortality associated with this procedure is lower, but more follow-up is needed before definite conclusions can be drawn.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: J.L. Harousseau, MD, Department of Hematology, Place Alexis Ricordeau, 44093 Nantes Cedex 01. E-mail: jean-luc.harousseau@univ-nantes.fr

References

  • 1.

    AttalMHarousseauJLStoppaAM. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med1996;335:9197.

    • Search Google Scholar
    • Export Citation
  • 2.

    ChildJAMorganGJDaviesFE. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med2003;348:18751883.

    • Search Google Scholar
    • Export Citation
  • 3.

    BladeJSamsonDReeceD. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol1998;102:11151123.

    • Search Google Scholar
    • Export Citation
  • 4.

    BladeJRosinolLSuredaA. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy; long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood2005;106:37553759.

    • Search Google Scholar
    • Export Citation
  • 5.

    BarlogieBKyleRAAndersonKC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol2006;24:929936.

    • Search Google Scholar
    • Export Citation
  • 6.

    HarousseauJLMilpiedNLaporteJP. Double-intensive therapy in high-risk multiple myeloma. Blood1992;79:28272833.

  • 7.

    VesoleDBarlogieBJagannathS. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood1994;84:950956.

    • Search Google Scholar
    • Export Citation
  • 8.

    BarlogieBJagannathSDesikanKR. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood1999;93:5565.

  • 9.

    AttalMHarousseauJLFaconT. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med2003;349:24952502.

    • Search Google Scholar
    • Export Citation
  • 10.

    SonneveldPvan der HoltBSegerenCM. Intensive versus double intensive therapy in untreated multiple myeloma: update analysis of the randomized phase III Hovon 24 study [abstract]. Haematologica2005;90(suppl 1):3738. Abstract PL8.01.

    • Search Google Scholar
    • Export Citation
  • 11.

    CavoMCelliniCZamagniE. Update on high-dose therapy–Italian studies [abstract]. Haematologica2005;90(suppl 1):3940. Abstract PL8.04.

    • Search Google Scholar
    • Export Citation
  • 12.

    GoldschmidtH. Single vs. double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [abstract]. Haematologica2005;90(suppl 1):38. Abstract PL8.02.

    • Search Google Scholar
    • Export Citation
  • 13.

    FermandJP. High dose therapy supported with autologous blood stem cell transplantation in multiple myeloma: long term follow-up of the prospective studies of the MAG group [abstract]. Haematologica2005;90(suppl 1):40. Abstract PL8.05.

    • Search Google Scholar
    • Export Citation
  • 14.

    DesikanRBarlogieBSawyerJ. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood2000;95:40084010.

    • Search Google Scholar
    • Export Citation
  • 15.

    FaconTAvet-LoiseauHGuillermG. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood2001;97:15661571.

    • Search Google Scholar
    • Export Citation
  • 16.

    BarlogieBShaughnessyJTricotG. Treatment of multiple myeloma. Blood2004;103:2032.

  • 17.

    BarlogieBTricotGRasmussenE. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood2006;107:26332638.

    • Search Google Scholar
    • Export Citation
  • 18.

    MoreauPHullinCGarbanF. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood2006;107:397403.

    • Search Google Scholar
    • Export Citation
  • 19.

    BarlogieBTricotGAnaissieE. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med2006;354:10211030.

  • 20.

    AttalMHarousseauJLLeyvrazS. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood2006;108:32893294

    • Search Google Scholar
    • Export Citation
  • 21.

    RajkumarVBloodEVesoleD. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol2006;24:431436.

    • Search Google Scholar
    • Export Citation
  • 22.

    CavoMZamagniETosiP. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood2005;106:3539.

    • Search Google Scholar
    • Export Citation
  • 23.

    OakerveeHEPopatRCurryN. PAD combination therapy (PS341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol2005;129:755762.

    • Search Google Scholar
    • Export Citation
  • 24.

    JagannathSDurieBGWolfJ. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol2005;129:776783.

    • Search Google Scholar
    • Export Citation
  • 25.

    HarousseauJLAttalMLeleuX. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica2006;91:14981505.

    • Search Google Scholar
    • Export Citation
  • 26.

    RajkumarSVHaymanSRLacyMQ. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood2005;106:40504053.

    • Search Google Scholar
    • Export Citation
  • 27.

    SiegelDSDesikanKRMehtaJ. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood1999;93:5154.

  • 28.

    BadrosABarlogieBSiegelE. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol2001;114:600607.

    • Search Google Scholar
    • Export Citation
  • 29.

    PalumboATrioloSArgentinoC. Dose-intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patients. Blood1999;94:12481253.

    • Search Google Scholar
    • Export Citation
  • 30.

    PalumboABringhenSPetrucciMT. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood2004;104:30523057.

    • Search Google Scholar
    • Export Citation
  • 31.

    FaconTMaryJYHulinC. Superiority of melphalan and prednisone + thalidomide over melphalan and prednisone alone and autologous stem cell transplantation of newly diagnosed elderly patients with multiple myeloma [abstract]. J Clin Oncol2006;24(suppl 1):1.

    • Search Google Scholar
    • Export Citation
  • 32.

    PalumboABringhenSCaravitaT. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet2006;367:825831.

    • Search Google Scholar
    • Export Citation
  • 33.

    MateosMVHernandezJMHernandezMT. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood2006;108:21652172.

    • Search Google Scholar
    • Export Citation
  • 34.

    GahrtonGSvenssonHCavoM. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol2001;113:209216.

    • Search Google Scholar
    • Export Citation
  • 35.

    LockhorstHMWuKVerdonckLF. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood2004;103:43624364.

    • Search Google Scholar
    • Export Citation
  • 36.

    KrogerNSayerHGSchwerdtfegerR. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood2002;100:39193924.

    • Search Google Scholar
    • Export Citation
  • 37.

    GiraltSAlemanAAnagnostopoulosA. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant2002;30:367373.

    • Search Google Scholar
    • Export Citation
  • 38.

    EinseleHSchäferHJHebartH. Follow-up of patients with progressive myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol2003;121:411418.

    • Search Google Scholar
    • Export Citation
  • 39.

    BadrosABarlogieBSiegelE. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol2002;20:12951303.

    • Search Google Scholar
    • Export Citation
  • 40.

    KrogerNSchillingGEinseleH. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic-dose reduced stem cell transplantation. Blood2004;103:40564061.

    • Search Google Scholar
    • Export Citation
  • 41.

    MaloneyDGMolinaAJSahebiF. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood2003;102:34473454.

    • Search Google Scholar
    • Export Citation
  • 42.

    GarbanFAttalMMichalletM. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood2006;107:34743480.

    • Search Google Scholar
    • Export Citation
  • 43.

    van de DonkNWKrogerNHegenbartU. Remarkable activity of agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative stem cell transplantation in multiple myeloma. Blood2006;107:34153416.

    • Search Google Scholar
    • Export Citation
  • 44.

    KrogerNZabelinaTAyukF. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol2006;34:770775.

    • Search Google Scholar
    • Export Citation

Article Information

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 14 14 2
PDF Downloads 0 0 0
EPUB Downloads 0 0 0